Kiromic BioPharma, Inc. (KRBP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kiromic BioPharma, Inc. (KRBP) with AI Score 44/100 (Weak). Kiromic BioPharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company focused on developing Gamma Delta T cell therapies for solid tumors. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Kiromic BioPharma, Inc. (KRBP) Healthcare & Pipeline Overview
Kiromic BioPharma, Inc. is an AI-driven biotechnology company specializing in allogeneic Gamma Delta T cell therapies targeting solid tumors. Their pipeline includes ALEXIS-ISO-1 and ALEXIS-PRO-1, novel cell therapies designed to enhance the natural potency of Gamma Delta T cells. The company operates in the competitive biotechnology sector.
Investment Thesis
Kiromic BioPharma's investment thesis centers on its innovative approach to cancer treatment using allogeneic Gamma Delta T cell therapies. The company's focus on solid tumors, a significant unmet medical need, presents a substantial market opportunity. Key value drivers include the successful development and commercialization of ALEXIS-ISO-1 and ALEXIS-PRO-1. Growth catalysts include advancing these product candidates through clinical trials and securing partnerships for manufacturing and distribution. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $0.00B and a P/E ratio of -0.17, the company's valuation reflects its early-stage development.
Based on FMP financials and quantitative analysis
Key Highlights
- Kiromic BioPharma is focused on developing allogeneic Gamma Delta T cell therapies for solid tumors.
- Lead product candidates include ALEXIS-ISO-1 targeting Isomesothelin and ALEXIS-PRO-1 targeting PD-L1.
- The company leverages artificial intelligence to enhance its cell therapy development process.
- Kiromic has established strategic alliances and licensing agreements to support its research and development efforts.
- The company's therapies aim to exploit the natural potency of Gamma Delta T cells to improve cancer treatment outcomes.
Competitors & Peers
Strengths
- Innovative AI-driven platform for cell therapy development.
- Focus on allogeneic Gamma Delta T cells, which may offer advantages over alpha-beta T cells.
- Strategic alliances and licensing agreements.
- Experienced management team with expertise in cell therapy and immuno-oncology.
Weaknesses
- Early-stage development with no approved products.
- Limited financial resources.
- High risk of clinical trial failures.
- Dependence on strategic alliances for manufacturing and distribution.
Catalysts
- Upcoming: Clinical trial results for ALEXIS-ISO-1 in solid tumors.
- Upcoming: Clinical trial results for ALEXIS-PRO-1 in solid tumors.
- Ongoing: Expansion of Kiromic's AI-driven platform for new cell therapy targets.
- Ongoing: Strategic partnerships for manufacturing and distribution.
- Ongoing: Advancements in Gamma Delta T cell therapy technology.
Risks
- Potential: Clinical trial failures for ALEXIS-ISO-1 and ALEXIS-PRO-1.
- Potential: Regulatory hurdles and delays in obtaining FDA approval.
- Potential: Competition from established pharmaceutical companies and emerging biotech firms.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on strategic alliances for manufacturing and distribution.
Growth Opportunities
- Advancing ALEXIS-ISO-1 through clinical trials represents a significant growth opportunity. Isomesothelin is overexpressed in several solid tumors, including mesothelioma, ovarian cancer, and lung cancer. Positive clinical data demonstrating the safety and efficacy of ALEXIS-ISO-1 could lead to accelerated regulatory approval and commercialization. The market for mesothelioma treatment alone is projected to reach billions of dollars by 2030, offering a substantial revenue opportunity for Kiromic.
- The development of ALEXIS-PRO-1 targeting PD-L1 presents another key growth avenue. PD-L1 is a well-validated target in immuno-oncology, and ALEXIS-PRO-1 has the potential to address a broad range of solid tumors. Successful clinical trials could position ALEXIS-PRO-1 as a competitive alternative to existing PD-1/PD-L1 inhibitors. The global market for PD-1/PD-L1 inhibitors is estimated to be over $40 billion, indicating the significant commercial potential of ALEXIS-PRO-1.
- Expanding the application of Kiromic's AI-driven platform to discover and develop new cell therapies represents a long-term growth opportunity. The company's artificial intelligence capabilities can be leveraged to identify novel targets and design more effective cell therapies. This platform approach could lead to a pipeline of innovative products addressing a wide range of cancers and other diseases. The market for AI-driven drug discovery is projected to experience rapid growth in the coming years.
- Establishing strategic partnerships with pharmaceutical companies for manufacturing and distribution can accelerate the commercialization of Kiromic's products. Partnering with established players can provide access to resources and expertise that are critical for navigating the complex regulatory landscape and reaching a broader patient population. These partnerships can also generate upfront payments and milestone payments, providing additional funding for research and development.
- Exploring the potential of Gamma Delta T cell therapies in combination with other cancer treatments, such as chemotherapy and radiation therapy, represents a promising growth area. Combination therapies can potentially enhance the efficacy of existing treatments and improve patient outcomes. Kiromic can conduct clinical trials to evaluate the safety and efficacy of its cell therapies in combination with other modalities. Positive results could lead to new treatment paradigms and expanded market opportunities.
Opportunities
- Advancing ALEXIS-ISO-1 and ALEXIS-PRO-1 through clinical trials.
- Expanding the application of its AI-driven platform to discover new cell therapies.
- Establishing partnerships with pharmaceutical companies for commercialization.
- Exploring combination therapies with other cancer treatments.
Threats
- Competition from established pharmaceutical companies and emerging biotech firms.
- Regulatory hurdles and delays in obtaining FDA approval.
- Changes in the regulatory landscape for cell therapies.
- Unfavorable clinical trial results.
Competitive Advantages
- Proprietary AI-driven platform for target identification and cell therapy design.
- Focus on allogeneic Gamma Delta T cells, which may offer advantages over alpha-beta T cells.
- Intellectual property protection for its cell therapy products and technologies.
- Strategic alliances and licensing agreements that provide access to resources and expertise.
About KRBP
Founded in 2006 and headquartered in Houston, Texas, Kiromic BioPharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company focused on developing innovative cancer treatments. The company leverages the natural potency of Gamma Delta T cells to target solid tumors, aiming to create more effective and accessible therapies. Kiromic's lead product candidates include ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy targeting PD-L1. These therapies are designed to overcome the limitations of traditional cancer treatments by harnessing the unique properties of Gamma Delta T cells. Kiromic has established license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has a strategic alliance agreement with Leon Office (H.K.) Ltd. Kiromic BioPharma, Inc. was formerly known as Kiromic, Inc. and changed its name in December 2019, reflecting its commitment to advancing biopharmaceutical solutions.
What They Do
- Develops allogeneic Gamma Delta T cell therapies for solid tumors.
- Utilizes artificial intelligence to identify and validate therapeutic targets.
- Conducts preclinical and clinical research to evaluate the safety and efficacy of its therapies.
- Manufactures cell therapy products for clinical trials.
- Seeks regulatory approval for its therapies from the FDA and other regulatory agencies.
- Establishes strategic partnerships for manufacturing, distribution, and commercialization.
Business Model
- Develops and licenses allogeneic Gamma Delta T cell therapies.
- Generates revenue through strategic alliances and licensing agreements.
- May generate future revenue through product sales upon regulatory approval.
- Focuses on research and development of innovative cancer treatments.
Industry Context
Kiromic BioPharma operates within the rapidly evolving biotechnology industry, specifically in the cell therapy and immuno-oncology sectors. The market for cell therapies is experiencing significant growth, driven by advancements in genetic engineering and a deeper understanding of the immune system's role in fighting cancer. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing similar therapies. Kiromic's focus on allogeneic Gamma Delta T cells differentiates it from companies primarily focused on alpha-beta T cell therapies, potentially offering advantages in terms of scalability and safety.
Key Customers
- Patients with solid tumors who are candidates for cell therapy.
- Hospitals and cancer centers that administer cell therapies.
- Pharmaceutical companies that may partner with Kiromic for commercialization.
- Research institutions that collaborate with Kiromic on research and development.
Financials
Chart & Info
Kiromic BioPharma, Inc. (KRBP) stock price: Price data unavailable
Latest News
No recent news available for KRBP.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KRBP.
Price Targets
Wall Street price target analysis for KRBP.
MoonshotScore
What does this score mean?
The MoonshotScore rates KRBP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Pietro Bersani CPA,
CEO
Pietro Bersani is the Chief Executive Officer of Kiromic Biopharma. His background includes experience as a Certified Public Accountant. His expertise lies in financial management and strategic leadership within the biotechnology sector. He brings a wealth of knowledge in corporate finance and accounting to Kiromic Biopharma. His previous roles have equipped him with the skills necessary to navigate the complexities of the pharmaceutical industry.
Track Record: Since becoming CEO, Pietro Bersani has focused on advancing Kiromic's pipeline of allogeneic Gamma Delta T cell therapies. He has overseen the company's research and development efforts, strategic alliances, and financial operations. Key milestones under his leadership include progressing ALEXIS-ISO-1 and ALEXIS-PRO-1 through preclinical development and initiating clinical trials. He is managing 44 employees.
KRBP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kiromic BioPharma may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited operating history, be in financial distress, or have chosen not to comply with higher reporting standards. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Assess the company's internal controls and risk management practices.
- Company has a functioning website and contact information.
- Company has a physical headquarters and employees.
- Company has strategic alliances and licensing agreements.
- Company has a board of directors and management team.
- Company is actively engaged in research and development activities.
What Investors Ask About Kiromic BioPharma, Inc. (KRBP)
What does Kiromic BioPharma, Inc. do?
Kiromic BioPharma, Inc. is a biotechnology company specializing in the development of allogeneic Gamma Delta T cell therapies for the treatment of solid tumors. The company utilizes an artificial intelligence-driven platform to identify and validate therapeutic targets. Their lead product candidates, ALEXIS-ISO-1 and ALEXIS-PRO-1, are designed to enhance the natural potency of Gamma Delta T cells to target and destroy cancer cells. Kiromic aims to provide innovative and effective cancer treatments by harnessing the unique properties of Gamma Delta T cells.
What do analysts say about KRBP stock?
AI analysis is pending for KRBP. Generally, biotechnology stocks are evaluated based on their pipeline progress, clinical trial results, and regulatory milestones. Key valuation metrics include potential peak sales for their therapies, probability of success in clinical development, and market share assumptions. Investors should monitor clinical trial data and regulatory updates to assess the company's prospects. The stock's performance will likely be driven by progress in advancing its product candidates through clinical development and towards commercialization.
What are the main risks for KRBP?
The main risks for Kiromic BioPharma include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory delays or denials could also hinder the commercialization of its therapies. Competition from companies with more resources and established market presence poses a significant challenge. Additionally, the company's limited financial resources and dependence on strategic alliances create financial and operational risks.
What are the key factors to evaluate for KRBP?
Kiromic BioPharma, Inc. (KRBP) currently holds an AI score of 44/100, indicating low score. Key strength: Innovative AI-driven platform for cell therapy development.. Primary risk to monitor: Potential: Clinical trial failures for ALEXIS-ISO-1 and ALEXIS-PRO-1.. This is not financial advice.
How frequently does KRBP data refresh on this page?
KRBP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KRBP's recent stock price performance?
Recent price movement in Kiromic BioPharma, Inc. (KRBP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative AI-driven platform for cell therapy development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KRBP overvalued or undervalued right now?
Determining whether Kiromic BioPharma, Inc. (KRBP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KRBP?
Before investing in Kiromic BioPharma, Inc. (KRBP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- AI analysis is pending for KRBP.